Nuclear Innovation Gets Funded, Long‐Term Bets Get Louder, and Drug Trials Miss the Mark

A nanotech firm secured fresh government backing from the DoE.

Elsewhere, a six-year insider lock-up signaled rare conviction, sending one cancer-focused stock soaring, while a highly anticipated therapy failed to deliver on fracture reduction, triggering a sharp selloff.

Most investors have never been shown this before.

Just before the Great Depression, a little-known market signal quietly began identifying historic winners—long before headlines caught on.

That same signal flagged several legendary stocks at prices that now seem impossible.

Now, with volatility rising again, it’s flashing green on three under-the-radar opportunities positioned to outperform into 2026.

Click here NOW — before it's too late.

Wall Street edged lower as tech cooled off following a strong year-end rally, with investors taking profits in high-flying AI names like Nvidia and Palantir.

Thin holiday trading volumes also muted broader market moves.

NVIDIA (NASDAQ: NVDA) has completed a $5 billion investment in Intel (NASDAQ: INTC), turning a strategic partnership into a balance-sheet-level commitment.

This was first outlined in September, but closing the deal now makes the message unmistakable: Nvidia is not just designing chips, it is locking in how and where they get made.

More than 214 million Intel shares were acquired through a private placement after regulatory clearance removed the final hurdle.

With that done, attention shifts from approvals to execution, and the timing is telling.

Intel Gets More Than Cash

For Intel, this is not just fresh capital. It is validation at a time when chip manufacturing is expensive, politically charged, and critical to national strategy.

Intel is rebuilding its role as a large-scale U.S. manufacturing partner, and having Nvidia financially anchored to that effort strengthens its position with customers, governments, and suppliers.

When you see who is willing to commit real money, credibility follows.

NVIDIA Buys Optionality

For Nvidia, the logic is control. AI demand is exploding, foundry capacity is tight, and supply chains remain fragile.

By tying itself financially to Intel, Nvidia adds a serious U.S.-based manufacturing option to its playbook.

You are witnessing a shift in which chip designers stop relying solely on external factories and begin embedding themselves more deeply in production. 

As artificial intelligence reshapes industries, maintaining optionality is essential to staying ahead.

It enables individuals and organizations to adapt quickly as technologies, markets, and opportunities evolve.

Fox Corporation (NASDAQ: FOXA) is making a sharp move to reshape its digital media future, using Tubi as the bridge between podcasts, advertising, and free streaming television.

A new multi-year deal gives Tubi Media Group exclusive distribution and ad rights to Audiochuck’s podcast lineup, including the massive hit Crime Junkie.

This is not a simple content add.

Fox plans to turn a top podcast into a full FAST channel, pushing audio brands into always-on video, and when you step back, the ambition becomes clear.

Podcasts Meet Always On Streaming

Podcasts bring loyalty and habit. FAST channels bring scale and constant presence. Fox is stitching the two together to create something stickier than a streaming library.

Instead of chasing endless new shows, Fox is extending proven franchises into new formats.

That lowers risk and deepens engagement in a market where attention is hard to hold, and you can see why this matters.

Tubi Becomes the Control Center

Tubi is no longer just a place to watch free shows. It is becoming a platform where Fox controls distribution, ad sales, and audience flow.

That control keeps economics in-house and gives advertisers premium, brand-safe inventory.

As media habits fragment, Fox is betting that blending audio and video under one roof is how you build relevance without subscriptions.

Inovio Pharmaceuticals (NASDAQ: INO) has hit a critical regulatory moment that will shape where the company goes next.

The FDA has accepted Inovio’s application for INO-3107, a treatment aimed at recurrent respiratory papillomatosis, a rare and painful disease linked to HPV.

Acceptance alone is meaningful. It tells you the FDA believes the data package is complete and credible enough for full review.

But the agency also signaled it will not grant accelerated approval, placing the drug on a standard review path with a decision expected in late 2026.

A Slower Path With Bigger Stakes

INO-3107 targets a disease where patients often face repeated surgeries just to manage symptoms.

The goal is simple: to reduce the need for invasive procedures by training the immune system to control the disease.

The FDA’s choice shifts the focus from speed to proof. If long-term benefits hold up, you will gain stronger confidence from doctors and patients, even if approval takes longer.

The Company Enters Execution Mode

This moment is bigger than one drug. Inovio is moving from experimental promise into late-stage execution, where evidence quality matters more than headlines.

Clinical data already show lasting benefit without constant dosing, which strengthens the case.

Now you are watching whether the company can meet FDA expectations, because if it does, you are not just approving a drug, you are validating the platform behind it.

👉 Click here to get our closing report to your cell for free!

Solidion Technology Inc [STI] $7.70 (+22.11%)

Solidion climbed after receiving its second U.S. Department of Energy grant, this time to scale up advanced nanofluids for nuclear reactor applications in collaboration with Oak Ridge.

Greenwich Lifesciences Inc [GLSI] $24.78 (+19.80%)

Greenwich LifeSciences surged after announcing a six-year insider lock-up extension, signaling long-term alignment and confidence ahead of key Phase III breast cancer trial milestones.

Nutriband Inc [NTRB] $5.57 (+16.04%)

Nutriband gained after selling a 90% stake in its Pocono Pharma unit for $5 million, retaining a stake in a new sustainable venture linked to Intel and Chevron veterans.

Ultragenyx Pharmaceutical Inc [RARE] $19.72 (-42.32%)

Ultragenyx plunged after its lead therapy for brittle bone disease failed to reduce fractures in two pivotal trials, missing its primary efficacy goals.

Momentus Inc [MNTS] $4.95 (-20.42%)

Momentus slid after revising its equity purchase agreement, allowing discounted share sales tied to market prices and fueling dilution concerns.

iPower Inc [IPW] $8.02 (-17.32%)

iPower dropped sharply after revealing a surprise $2.2 million investment in Bitcoin and Ethereum, marking a risky pivot from its core operations.

The next leg of AI growth is set to emerge from advanced data infrastructure, a segment gaining powerful momentum beneath the surface.

Leaders in this space are showing strong operational expansion, increasing government interest, and growing enterprise adoption.

These developments are quietly creating high-probability setups for early movers.

As demand accelerates, positioning inside this sector could produce significant compounding potential.

A FREE report highlights all nine opportunities poised to benefit from this surge.

Download your FREE Report Now.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.